| T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection |
78 |
| Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC |
62 |
| Tumor Microenvironment Characterization in Gastric Cancer Identifies Prognostic and Immunotherapeutically Relevant Gene Signatures |
59 |
| Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager |
54 |
| Exosomes Shuttle TREX1-Sensitive IFN-Stimulatory dsDNA from Irradiated Cancer Cells to DCs |
51 |
| Programmed Cell Death Ligand 1 (PD-L1) Signaling Regulates Macrophage Proliferation and Activation |
47 |
| Exosomes Released from Tumor-Associated Macrophages Transfer miRNAs That Induce a Treg/Th17 Cell Imbalance in Epithelial Ovarian Cancer |
43 |
| NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors |
38 |
| PPAR-Induced Fatty Acid Oxidation in T Cells Increases the Number of Tumor-Reactive CD8(+) T Cells and Facilitates Anti-PD-1 Therapy |
38 |
| Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma |
38 |
| Reducing Ex Vivo Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells |
36 |
| High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model |
35 |
| A Gene Signature Predicting Natural Killer Cell Infiltration and Improved Survival in Melanoma Patients |
33 |
| The Tumor Immune Microenvironment Drives a Prognostic Relevance that Correlates with Bladder Cancer Subtypes |
33 |
| IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype |
32 |
| Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer |
32 |
| A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti-PD-(L)1 and Anti-CTLA-4 in Preclinical Models |
31 |
| YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma |
30 |
| FAP Delineates Heterogeneous and Functionally Divergent Stromal Cells in Immune-Excluded Breast Tumors |
30 |
| The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy |
30 |
| Immune Cell Gene Signatures for Profiling the Microenvironment of Solid Tumors |
29 |
| Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma |
29 |
| Lactate-Mediated Acidification of Tumor Microenvironment Induces Apoptosis of Liver-Resident NK Cells in Colorectal Liver Metastasis |
29 |
| Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade |
26 |
| Prognostic Significance of PD-L1(+) and CD8(+) Immune Cells in HPV+ Oropharyngeal Squamous Cell Carcinoma |
26 |
| Intratumoral CD8(+) T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity |
25 |
| Radiotherapy and CTLA-4 Blockade Shape the TCR Repertoire of Tumor-Infiltrating T Cells |
25 |
| PD-L1 Binds to B7-1 Only In Cis on the Same Cell Surface |
24 |
| PD-L1 Mediates Dysfunction in Activated PD-1(+) NK Cells in Head and Neck Cancer Patients |
24 |
| Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into CheckpointResponsive Tumors by Reprogramming Tumor-Infiltrating MDSCs |
23 |
| Peptide Blocking of PD-1/PD-L1 Interaction for Cancer Immunotherapy |
23 |
| Hypoxia-Induced VISTA Promotes the Suppressive Function of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment |
22 |
| Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer |
21 |
| Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors |
21 |
| Targeting Hypoxia-Induced Carbonic Anhydrase IX Enhances Immune-Checkpoint Blockade Locally and Systemically |
21 |
| The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma |
21 |
| Siglec-9 Regulates an Effector Memory CD8(+) T-cell Subset That Congregates in the Melanoma Tumor Microenvironment |
20 |
| Treg Fragility: A Prerequisite for Effective Antitumor Immunity? |
20 |
| Antibody-Cytokine Fusions: Versatile Products for the Modulation of Anticancer Immunity |
20 |
| Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma |
20 |
| Successful Treatment of HIV-Associated Kaposi Sarcoma with Immune Checkpoint Blockade |
20 |
| Predictive Biomarkers for Checkpoint Immunotherapy: Current Status and Challenges for Clinical Application |
19 |
| Stromal Fibroblasts Mediate Anti-PD-1 Resistance via MMP-9 and Dictate TGF beta Inhibitor Sequencing in Melanoma |
19 |
| Tumor Cells Hijack Macrophage-Produced Complement C1q to Promote Tumor Growth |
19 |
| Fusobacterium nucleatum in Colorectal Cancer Relates to Immune Response Differentially by Tumor Microsatellite Instability Status |
18 |
| The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity |
18 |
| Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4(+)Foxp3(-) Cell-Mediated Modulation of CD103(+) Dendritic Cells |
18 |
| Automated Analysis of Lymphocytic Infiltration, Tumor Budding, and Their Spatial Relationship Improves Prognostic Accuracy in Colorectal Cancer |
18 |
| Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy |
18 |
| Mitochondria! Morphological and Functional Reprogramming Following CD137 (4-1BB) Costimulation |
17 |
